Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-10-18 17:03:41
Reporting Period:
Accepted Time:
2018-10-18 17:03:41
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1615219 Flex Pharma Inc. FLKS () DE
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543245 Longwood Fund Ii, L.p. C/o Flex Pharma, Inc.
800 Boylston Street
Boston MA 02199
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-10-16 3,212,861 $0.92 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. Represents 2,697,264 shares sold by Longwood Fund II, L.P. ("Longwood Fund II") and 515,597 shares sold by Longwood Fund III, L.P. ("Longwood Fund III").
  3. Longwood Fund II GP, LLC is the General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D. and Richard Aldrich (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC. The Managers have delegated their voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares") to a committee comprised of three members, two of which such members include the Managers (the "Longwood Committee").
  4. The Longwood Committee approves investment and voting decisions by a majority vote, and no individual member has sole control or voting power over the Longwood Shares. Each of Longwood Fund II GP, LLC, Longwood Fund III GP, LLC, the Managers and the members of the Longwood Committee disclaim beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.